[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260261-280; 281-300; 301-320

NICE TAs 261-280

 

REF

 

TITLE

 

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

TA261

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban (TA261)

2.8 Anticoagulants: 2.8.2 Oral anticoagulants

 

TA262

Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal) (TA262)

No drug implications

 

TA263

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

 

Not supported

 

TA264

Stroke (acute, ischaemic) - alteplase (TA264)

2.10 Stable angina, acute coronary syndromes and fibrinolysis: 2.10.2 Fibrinolytic drugs

 

TA265

Bone metastases from solid tumours - denosumab (TA265)

6.6 Drugs affecting bone metabolism: 6.6.2 Bisphosphonates and other drugs affecting bone metabolism.

 

TA266

Cystic fibrosis - mannitol dry powder for inhalation (TA266)  

 3.7 Mucolytics

 

 

TA267

Chronic heart failure - ivabradine (TA267)

2.6 Nitrates and calcium-channel blockers: 2.6.3 Other Anti-anginal drugs

 

TA268

Melanoma (stage III or IV) - ipilimumab (TA268)

 

EMCN algorithm

DHFT protocol

TA269

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)

 

EMCN algorithm

DHFT protocol 

TA270

Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)

No drug implications

 

TA271

Diabetic macular oedema - fluocinolone acetonide intravitreal implant (TA271)

Not recommended by NICE

 

TA272

Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)

Not recommended by NICE

Not supported

TA273

Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)

Not recommended by NICE

 

TA274

Macular oedema (diabetic) - ranibizumab (TA274)

11.8.2 Ocular diagnostic and peri-operative preparations

 

TA275

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)

2.8.2 Oral anticoagulants

 

TA276

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)

5.1 Antibacterial: Tetracyclines, aminoglycosides, macrolides, clindamycin

and

5.1 Antibacterial: Some other antibiotics, trimethoprim, antituberculous drugs

 

TA277

 

Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277)  

 TA Terminated

 

TA278

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) (TA278)

3.4 Antihistamines 

 

TA279

Vertebral fractures - vertebroplasty and kyphoplasty (TA279)

No drug implications

 

TA280

Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) (TA280)

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout